A5064344218- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Statistical Methods in Clinical Trials
- Cancer Genomics and Diagnostics
- Statistical Methods and Inference
- Cancer Risks and Factors
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Advanced Causal Inference Techniques
- Healthcare Policy and Management
- Cancer, Lipids, and Metabolism
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Bladder and Urothelial Cancer Treatments
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- BRCA gene mutations in cancer
- Hormonal and reproductive studies
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
Fred Hutch Cancer Center
2016-2025
University of Washington
2014-2024
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
OHSU Knight Cancer Institute
2019-2024
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2005-2023
Cancer Research Center
2005-2023
Oregon Health & Science University
2014-2023
Bristol-Myers Squibb (Germany)
2004-2023
Kaiser Permanente Washington Health Research Institute
2011-2023
Exelixis (United States)
2023
Abstract In the United States, colorectal cancer (CRC) is fourth most common diagnosed among adults and second leading cause of death from cancer. For this guideline update, American Cancer Society (ACS) used an existing systematic evidence review CRC screening literature microsimulation modeling analyses, including a new evaluation age to begin by race sex additional that incorporates changes in US incidence. Screening with any one multiple options associated significant reduction incidence...
Breast cancer is a leading cause of premature mortality among US women. Early detection has been shown to be associated with reduced breast morbidity and mortality.To update the American Cancer Society (ACS) 2003 screening guideline for women at average risk cancer.The ACS commissioned systematic evidence review literature inform supplemental analysis mammography registry data address questions related interval. Formulation recommendations was based on quality judgment (incorporating values...
The guideline purpose is to provide the urologist with a framework for early detection of prostate cancer in asymptomatic average risk men.A systematic review was conducted and summarized evidence derived from over 300 studies that addressed predefined outcomes interest (prostate incidence/mortality, quality life, diagnostic accuracy harms testing). In addition evidence, panel considered values preferences expressed clinical setting (patient-physician dyad) rather than having public health...
Background: Overdiagnosis of clinically insignificant prostate cancer is considered a major potential drawback prostate-specific antigen (PSA) screening. Quantitative estimates the magnitude this problem are, however, lacking. We estimated rates overdiagnosis due to PSA testing that are consistent with observed incidence in United States from 1988 through 1998. was defined as detection otherwise would not have been diagnosed within patient's lifetime. Methods: developed computer simulation...
Cancer-specific medical care costs are used by health service researchers, decision analysts, and policymakers. The SEER-Medicare database is a unique data resource that makes it possible to derive incidence- prevalence-based estimates of cancer-related site stage disease, treatment approach, for age gender strata individuals older than 65 years.This paper describes the cost-related available in database, discusses techniques methods have been various cost from these data. limitations as...
Abstract The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 through 65 (preferred); if HPV is not available, then aged to should be screened cotesting (HPV in combination cytology) or cytology alone 3 (acceptable) ( strong recommendation ). ACS >65 who have no history of intraepithelial neoplasia grade 2 more severe disease within the past years,...
The time by which prostate-specific antigen (PSA) screening advances prostate cancer diagnosis, called the lead time, has been reported several studies, but results have varied widely, with mean times ranging from 3 to 12 years. A quantity that is closely linked overdiagnosis frequency, fraction of screen-detected cancers would not diagnosed in absence screening. Reported estimates also variable, 25% greater than 80% cancers. We used three independently developed mathematical models...
Abstract Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of disease, when resource utilization is intensive. Yet, number women living with MBC in United States unknown. The objective this article to use population-based data estimate prevalence MBC. Methods: We used a back-calculation method from U.S. mortality survival Surveillance, Epidemiology End Results (SEER)...
Estimation of the average total cost for treating patients with a particular disease is often complicated by fact that survival times are censored on some study subjects and their subsequent costs unknown. The naive sample observed from all or uncensored cases only can be severely biased, standard analysis techniques not applicable. To minimize bias induced censoring, we partition entire time period interest into number small intervals estimate either sum Kaplan-Meier estimator probability...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations prostate cancer screening healthy men who have elected to participate an early detection program. focus on minimizing unnecessary procedures and limiting the of indolent disease. These Insights summarize Panel's most significant discussions 2016 guideline update, which included issues surrounding high-risk populations (ie, African Americans, BRCA1/2 mutation...
Clinical trials test the efficacy of a treatment in select patient population. We examined whether cancer clinical trial patients were similar to nontrial, "real-world" with respect presenting characteristics and survival.We reviewed SWOG national consortium database identify candidate trials. Demographic factors, stage, overall survival for standard arms compared nontrial control subjects selected from Surveillance, Epidemiology, End Results program. Multivariable analyses using Cox...
The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in implementation screening, biopsy, follow-up. This is Part I two-part series that focuses screening. Please refer II for discussion initial repeat biopsies as well biopsy technique. systematic review utilized inform this guideline was conducted by an independent methodological consultant. based searches Ovid MEDLINE Embase Cochrane...
Abstract Lung cancer is the leading cause of mortality and person‐years life lost from among US men women. Early detection has been shown to be associated with reduced lung mortality. Our objective was update American Cancer Society (ACS) 2013 screening (LCS) guideline for adults at high risk cancer. The intended provide guidance health care providers their patients who are due a history smoking. ACS Guideline Development Group (GDG) utilized systematic review LCS literature commissioned...
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on pros and cons. These Insights summary of recent updates regard testing protocol, use multiparametric MRI, management negative biopsy results optimize clinically significant cancer minimize indolent disease.
The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in implementation screening, biopsy, follow-up. This is Part II two-part series focusing initial repeat biopsies, biopsy technique. Please refer I for discussion screening recommendations. systematic review utilized inform this guideline was conducted by an independent methodological consultant. based searches Ovid MEDLINE Embase...
Background: Mammography screening can lead to overdiagnosis—that is, screen-detected breast cancer that would not have caused symptoms or signs in the remaining lifetime. There is no consensus about frequency of overdiagnosis. Objective: To estimate rate overdiagnosis contemporary mammography practice accounting for detection nonprogressive cancer. Design: Bayesian inference natural history using individual and diagnosis records, allowing preclinical Combination fitted model with life-table...